MEMORANDUM. Re: Guidance for follow-up of newly-arrived individual with Class B1 Tuberculosis Pulmonary Tuberculosis, no treatment

Similar documents
MEMORANDUM. Re: Guidance for follow-up of newly-arrived Individual with a Class B1 Tuberculosis Extrapulmonary Tuberculosis

Northwestern Polytechnic University

Latent Tuberculosis Infection Reporting Instructions for Civil Surgeons Using CalREDIE Provider Portal

CDC IMMIGRATION REQUIREMENTS:

Clinical Practice Guideline

Appendix B. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)

TB Clinical Guidelines: Revision Highlights March 2014

Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease

Revised Technical Instructions for Civil Surgeons. October 9, 2018

Student Health Requirements Master of Arts, Biomedical Sciences Program

Stop TB Poster (laminated copies are available from TB Control: )

Peggy Leslie-Smith, RN

INDEX CASE INFORMATION

CUSOM Student Health Immunization Requirements

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers

Utilizing All the Tools in the TB Toolbox

Diagnosis and Medical Management of Latent TB Infection

UC DavisTB Screening Requirement: How to submit your TB Health Assessment Form

Audit of management of TB in HIV co-infected patients: survey of clinic arrangements

TB in Corrections Phoenix, Arizona

TB Update: March 2012

TUBERCULOSIS CONTACT INVESTIGATION

Director, University Health Services. Medical Director

New Standards for an Old Disease:

TB Intensive Minneapolis, Minnesota September 23-26, 2008

Tuberculosis Tools: A Clinical Update

Appendix C. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)

Tuberculosis (TB) and Infection Control PICNET Conference April 12, 2013

2017/2018 Annual Volunteer Tuberculosis Notice

Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis

Appendix B. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)

Communicable Disease Control Manual Chapter 4: Tuberculosis. Assessment and Follow-Up of TB Contacts

TB Contact Investigation

Update on the 2007 TB Technical Instructions. Adriene Rister TB Control Coordinator Mainely TB: April 14, 2011

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010

Contact Investigation

Tuberculosis 6/7/2018. Objectives. What is Tuberculosis?

FLORIDA DEPARTMENT OF JUVENILE JUSTICE DETENTION SERVICES FACILITY MEDICAL POLICIES

17-ID-09. Title: Establishing a Case Definition for Latent TB Infection (TB Infection)

A Mobile Health Intervention Utilizing Community Partnership to Improve Access to Latent Tuberculosis Infection Treatment

These recommendations will remain in effect until the national shortage of PPD solution has abated.

Diagnosis and Treatment of Tuberculosis, 2011

Tuberculosis What you need to know. James Zoretic M.D., M.P.H. Regions 2 and 3 Director

Yakima Health District BULLETIN

Preventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers. Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program

TB Classification (ATS/CDC)

TUBERCULOSIS CONTACT INVESTIGATION

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

Summary of Immunization Options

Santa Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, 2014

New Tuberculosis Guidelines. Jason Stout, MD, MHS

Tuberculosis - clinical forms. Dr. A.Torossian,, M.D., Ph. D. Department of Respiratory Diseases

Tuberculosis: A Provider s Guide to

TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of

Tuberculosis (TB) Fundamentals for School Nurses

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant

The Epidemiology of Tuberculosis in Minnesota,

TB BASICS: PRIORITIES AND CLASSIFICATIONS

Diagnosis Latent Tuberculosis. Disclosures. Case

Making the Diagnosis of Tuberculosis

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

Investigation of Contacts of Persons with Infectious Tuberculosis, 2005

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

Latent tuberculosis infection

Detection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges

Nucleic Acid Amplification Test for Tuberculosis. Heidi Behm, RN, MPH Acting TB Controller HIV/STD/TB Program Oregon, Department of Health Services

TB is Global. Latent TB Infection (LTBI) Sharing the Care: Working Together. September 24, 2014

(a) Infection control program. The facility must establish an infection control program under which it--

Strategic Peer-Enhanced Care and Treatment Retention Model (SPECTRuM) Initiative. Intervention Protocol #2

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH

TB Contact Investigation Basics

Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal

Latent Tuberculosis Best Practices

CHAFFEY COLLEGE SCHOOL OF HEALTH SCIENCES HEALTH EXAMINATION FORM

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB

Tuberculosis in Chicago 2007

Interpretation of TST & IGRA results. Objectives

TB in Corrections Phoenix, Arizona

Tuberculosis Populations at Risk

COFM Immunization Policy 2016

Why need to havetb Clearance. To Control and Prevent Tuberculosis

Self-Study Modules on Tuberculosis

Fundamentals of Tuberculosis (TB)

TB-Free California: How close are we? How can we get closer?

Management of Patients with TB Infection Catalina Navarro, RN, BSN April 7, 2015

11/3/2009 SECOND EDITION Madhukar Pai McGill University. ISTC Training Modules Introduction

Asking the Right Questions. A Visual Guide to Tuberculosis Case Management for Nurses. Reference Guide

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis

TB in the Patient with HIV

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

MAVEN Release Notes Monroe Release Released on July 17, 2014

Tuberculosis Screening and Targeted Testing of College and University Students: Developing a Best Practice Approach:

TB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

Table 9. Policy for Tuberculosis Surveillance and Screening

Arizona Annual Tuberculosis Surveillance Report

International Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007

Diagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015

HEALTH SERVICES POLICY & PROCEDURE MANUAL

Transcription:

MEMORANDUM To: From: Local Board of Health John Bernardo, MD, Tuberculosis Medical Officer Jennifer Cochran, MPH, Division Director Division of Global Populations and Infectious Disease Prevention Bureau of Infectious Disease and Laboratory Sciences Department of Public Health Re: Guidance for follow-up of newly-arrived individual with Class B1 Tuberculosis Pulmonary Tuberculosis, no treatment An immigrant or refugee with a Class B1 Tuberculosis (TB), Pulmonary TB, No treatment condition has recently arrived from overseas and settled in your area. Class B1 TB, Pulmonary TB, No treatment is assigned to persons who have a medical history, physical examination, HIV, or chest radiograph findings suggestive of pulmonary tuberculosis, but have negative AFB sputum smears and cultures and are not diagnosed with tuberculosis or can wait to have tuberculosis treatment started after immigration. Persons with Class B1 TB conditions are at high risk for TB. Evaluation by public health is required for all individuals with Class B1 TB conditions in order to rule out active pulmonary TB or establish a diagnosis of latent TB infection, and to treat the condition. This evaluation should be done within 30 days after arrival in the U.S., if possible. CDC Technical Instructions provide guidance for the overseas medical examination and specifications for classifying TB conditions. The Massachusetts Department of Public Health (MDPH) requests your cooperation and assistance by completing the following: 1) Follow the Class B1 TB, Pulmonary TB, No treatment instructions on the attached guidance, LBOH and TB Clinic Procedures for evaluation of this immigrant or refugee. 2) Forward all of the enclosed/attached documents to the TB clinic prior to the scheduled visit. http://www.mass.gov/eohhs/docs/dph/cdc/tb/regional-clinic-list.pdf 3) Follow up with the TB clinic after the scheduled appointment to obtain a copy of the initial evaluation clinic form and the CDC Follow-up Worksheet. If the patient misses the appointment, please contact him/her and reschedule the appointment. 4) Return the completed CDC Follow-up Worksheet and Initial Clinic Evaluation to the MDPH Division of Global Populations and Infectious Disease Prevention. 5) Consider any other recently-arrived family or household members to also be at risk for TB infection and, if they were not evaluated overseas, use this opportunity to administer a tuberculin

skin test (TST) or interferon-gamma release assay (IGRA). If the TST is positive (> 10 mm induration) or the IGRA is positive, report them to MDPH and refer them to a TB clinic for a medical evaluation, chest radiograph, and treatment options. Enclosed/attached documents include: 1) The individual s overseas medical examination reports including the TB evaluation, which has documentation of chest X-ray (CXR), sputum smear and culture results, and TST or IGRA results, when indicated, for the individual arrival; 2) The CDC Follow-up Worksheet form with demographics and destination address filled in, and worksheet guidelines; 3) The LBOH and TB clinic follow-up procedures for Class B1 TB, Pulmonary TB, No treatment condition; 4) Detailed instructions for completing the domestic evaluation and documenting the findings on the form. A Community Health Worker will be assigned to the arrival as available. If you have any questions or need assistance with outreach, please contact the Division of Global Populations and Infectious Disease Prevention (617-983-6970). Please refer to the overseas documents attached to determine if this arrival is an immigrant or refugee. Please return Follow-up Worksheet and clinic forms to: Division of Global Populations and Infectious Disease Prevention Bureau of Infectious Disease and Laboratory Sciences Department of Public Health 305 South Street Jamaica Plain, MA 02130 Fax: 617-983-6990

LBOH AND TB CLINIC PROCEDURES: CLASS B1 TB, PULMONARY, No Treatment CDC Definition of Class B1 TB, Pulmonary Condition No Treatment Class B1 TB, Pulmonary: Persons who have a medical history, physical examination, HIV, or chest radiograph findings suggestive of pulmonary tuberculosis, but have negative AFB sputum smears and cultures and are not diagnosed with tuberculosis or can wait to have tuberculosis treatment started after immigration. Persons with a Class B1 TB, Pulmonary No Treatment condition, were not infectious at the time of the overseas medical examination and had three negative sputum cultures. The overseas medical examination may have been done up to three months prior to departure, with another screening conducted within three weeks of departure. However, the examiner is advised to exercise clinical judgment in performing the medical examination. LOCAL PUBLIC HEALTH Follow-up: 1) Contact the arrival immediately to introduce the evaluation process. 2) If an overseas tuberculin skin test (TST) was not done or was negative, administer a TST or call MDPH at 617-983-6970 to request a lab order for IGRA. 3) All persons with a Class B1 TB, Pulmonary condition without treatment overseas need to be evaluated at a state-supported TB clinic, regardless of the TST or IGRA result. Schedule an appointment as soon as possible at the nearest TB clinic for a medical evaluation within 30 days. Instruct the individual to bring his/her overseas chest radiograph (CXR) and any documents and medications to the appointment. a. An individual with Class B1 TB, HIV infection and negative overseas chest X-ray, and with a negative TST and negative IGRA, can have their domestic TB evaluation completed by an infectious disease provider outside of TB clinic. The complete evaluation includes both TST and IGRA. The provider should complete the TB worksheet, with ATS classification, and fax it to 617-983-6990. b. An individual with Class B1 TB, HIV infection and negative overseas chest X-ray, and with a positive TST or positive IGRA should be referred to TB clinic. c. An individual with Class B1 TB due to HIV infection and abnormal overseas chest X-ray, should be referred to TB clinic with any TST or IGRA result. TB Clinic Follow-up: 1) Review TST or IGRA status: A TST reaction of 5 mm or greater is positive in persons with an abnormal chest X-ray. 2) Review TB history with the patient: History, including TB treatment history if applicable, may be found on the visa medical examination report (DS-2053). Review any overseas treatment with the patient. In some cases, patients may have received treatment not documented on the DS forms. 3) Perform a physical examination and take a chest X-ray: A new CXR should be taken. The patient should have his/her overseas CXR available for comparison. Compare the U.S. CXR to the overseas

CXR (if available) with special attention to possible active tuberculosis, and document your interpretation of both CXR s on the CDC Follow-up Worksheet. 4) Collect sputum: Sputum specimens for acid fast bacilli smear and culture are to be obtained at the provider s discretion, based on symptoms and clinical and radiographic evaluation. 5) Prescribe treatment as appropriate according to the CDC/ATS guidelines: If sputum samples are obtained, and if clinical suspicion is low for active disease, a treatment decision may be deferred, pending laboratory results. Alternatively, if treatment is initiated, a standard four-drug regimen should be prescribed until final laboratory data are reported. CDC/ATS treatment guidelines available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm 6) Documentation: Document your findings and the initiation of treatment on the CDC Follow-up Worksheet. 7) Report persons with suspected pulmonary or extrapulmonary TB disease and/or who are started on treatment for active disease within one working day to the MDPH Office of Integrated Surveillance and Informatics Services (fax to: 617-983-6813). Do not wait for culture confirmation. 8) Return the Follow-up Worksheet : Send the worksheet with sections C E2 completed and a copy of the TB clinic forms to the Local Board of Health of the arrival s town/city of residence. (Note that, per usual protocols, the clinic form is also faxed to MDPH.) If you have any questions about the evaluation process or forms, please contact the Division of Global Populations and Infectious Disease Prevention (617-983-6970).

INSTRUCTIONS FOR COMPLETING THE FOLLOW-UP WORKSHEET FOR REFUGEE AND IMMIGRANT ARRIVALS WITH TB CLASS CONDITIONS: The initial evaluation of an arrival with a TB Class condition will be considered complete when: A diagnosis is made (section D3 of the form) based on a complete evaluation and a treatment start date is known for those individuals initiating therapy for active TB disease or latent TB infection, or The provider is unable to complete the evaluation and the reason for this is indicated (section D2). Section A Demographic Section B Jurisdictional Section C U.S. Evaluation TST or IGRA U.S. Review of Overseas CXR Domestic CXR U.S. Microscopy / Bacteriology Will be completed before you receive the paperwork. C1 Indicate date of the initial evaluation C2 Document the domestic TST date, mm induration (not redness), and interpretation C3 If you use an interferon-gamma release assay (IGRA), record the date and results. C4 Arrivals should bring their overseas CXR film(s) with them to their exam. Indicate if arrival provided the overseas CXR for review. Check Not Verifiable if you suspect the CXR does not belong to the arrival (e.g. fraudulent or mistaken CXR) C5-6 Document your (or your radiologist s) interpretation of the overseas CXR film. C7-10 Document date and results of domestic CXR. C11 - Compare domestic CXR to overseas film. Document the results of the comparison. C12 Document if sputum specimens were collected and smear results on the form. U.S. Review of Overseas Treatment Section D Disposition Diagnosis C13-17 [If applicable] Document your interpretation of the overseas treatment based on your review of overseas documents and information provided by the patient. D1-D2 When you are finished with the initial evaluation, indicate the date of your final diagnosis and your treatment recommendation. If unable to initiate or complete the evaluation, indicate the reason. D3 Indicate final diagnosis according to ATS classification system. D4 Leave blank. For MDPH use only.

Section E U.S. Treatment E1-E2 Check appropriate box regarding treatment and document start date, if applicable. E3 Return this information when treatment has ended. Section F - Comments Write any additional comments. Section G Physician Signature Sign and date form. When you have finished the initial evaluation (including disposition) and indicated treatment start date (when applicable), return this worksheet and clinic forms to the local board of health of the arrival s town/city of residence. For questions please contact the Division of Global Populations and Infectious Disease Prevention at 617-983-6970. Evaluated using the CDC s 2009 Technical Instructions